1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Divi's Laboratories Limited

Divi's Laboratories Limited

8,925.00
INR
-237.00
(-2.59%)
104.73EPS
62.82P/E
1.75TMarket Cap
Nov 09Next Earn
Divi's Laboratories Limited
NSE:DIVISLAB
(National Stock Exchange of India)

Recent

price

8,925.00

P/E

ratio

62.82

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
49.72
70.24
80.79
95.38
117.34
141.98
152.68
143.42
180.96
199.31
258.35
331.46
288.73
293.67
351.27
394.62
411.42
Revenue per Share
16.21
20.1
22.68
29.13
32.08
42.41
39.95
33.04
50.96
51.85
74.75
111.52
68.71
60.27
82.53
96.73
104.73
Basic EPS, GAAP
6.19
1.85
5.27
11.69
19.55
24.19
29.14
18.91
8.33
1.23
39.05
45.15
74.81
9.72
8.1
8.21
- -
Free Cash Flow per Basic Share
3.49
5.81
7.55
8.77
11.7
24.07
- -
12.03
12.06
38.58
- -
20
29.98
29.98
29.98
30.02
- -
Dividend per Share
67.78
80.29
94.2
111.63
143.98
161.73
201.81
223.18
262.07
275.36
350.12
441.79
480.92
511.21
563.87
631.37
- -
Book Value per Share
67.78
80.29
94.2
111.63
143.84
161.62
201.69
222.94
261.92
275.22
349.93
441.51
480.73
511.06
563.72
631.15
- -
Tangible Book Value per Share
265
265
265
265
265
265
265
265
265
265
265
265
265
265
265
265
266
Basic Weighted Avg Shares
13,165
18,639
21,448
25,321
31,149
37,690
40,533
38,075
48,038
52,912
68,583
87,992
76,650
77,960
93,250
104,760
109,250
Sales/Revenue/Turnover
34.01
33.82
34.52
36.71
33.35
34.62
33.66
29.59
35.61
31.01
38.14
40.61
26.44
23.5
27.57
28.44
30.43
Operating Margin (%)
534
621
769
921
1,360
1,182
1,233
1,425
1,689
1,862
2,556
3,115
3,430
3,780
4,020
4,630
4,830
Depreciation Expense
4,293
5,333
6,020
7,733
8,515
11,258
10,604
8,770
13,527
13,765
19,843
29,605
18,240
16,000
21,910
25,680
27,810
Net Income, GAAP
9.13
21.65
22.94
21.96
20.57
19.17
24
28.78
27.08
24.34
25.57
19.63
23.01
26.03
24.86
24.2
23.93
Effective Tax Rate (%)
32.61
28.61
28.07
30.54
27.34
29.87
26.16
23.03
28.16
26.02
28.93
33.64
23.8
20.52
23.5
24.51
25.46
Profit Margin (%)
11,308
11,972
13,097
16,289
23,175
25,075
33,511
38,817
38,033
37,530
50,623
71,560
82,110
83,970
86,290
90,530
- -
Working Capital
49
- -
- -
- -
- -
- -
- -
- -
- -
45
37
29
30
20
20
50
- -
LT Debt
17,975
21,315
25,006
29,633
38,223
42,933
53,574
59,248
69,572
73,099
92,946
117,282
127,670
135,710
149,690
167,610
- -
Total Equity
24.16
24.65
24.14
26.12
23.97
25.64
21.32
14.01
19.08
17.19
23.33
27.28
12.74
10.24
13.48
13.88
- -
Return on Invested Capital (%)
25.58
26.76
25.56
28.09
24.95
27.56
21.82
15.42
20.75
19.16
23.84
28.16
14.89
12.16
15.36
16.29
- -
Return on Capital (%)
25.9
27.15
25.99
28.31
25.1
27.74
21.98
15.55
21
19.3
23.9
28.16
14.89
12.15
15.35
16.19
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
20
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
50
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
265
265
Market Capitalization
1,697,008
1,578,742
1,746,518

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
110,960
- -
Cash, Cash Equivalents & STI
- -
32,360
- -
Accounts Receivable, Net
- -
29,840
- -
Inventories
- -
39,540
- -
Total Current Liabilities
- -
20,430
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
20
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.86%
12.72%
11.97%
Free Cash Flow
289.08%
-4.2%
1.4%
Net Income, GAAP
12.97%
10.53%
17.21%
Sales/Revenue/Turnover
11.65%
9.81%
12.34%
Total Cash Common Dividend
- -
- -
0.13%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
21,180
23,380
23,190
25,850
93,250
2026
24,100
- -
26,040
28,310
104,760
2027
30,800
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
16.2
19.2
22.2
24.93
82.53
2026
20.49
- -
21.98
28.31
96.73
2027
33.95
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
29.98
2026
- -
- -
- -
- -
30.02
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Merck & Company, Inc. (NYSE:MRK)
Business
Divi's Laboratories Limited (DIVISLAB.NS) manufactures active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients; provides custom synthesis services for generic APIs and advanced intermediates to global pharmaceutical companies; and supplies carotenoids such as beta-carotene, astaxanthin, lycopene and canthaxanthin, along with vitamins and lutein to the nutritional, pharmaceutical, food, beverage and feed industries. The company offers a portfolio of approximately 30 commercial generic APIs across therapeutic categories including antidepressants (e.g., bupropion HCl, venlafaxine HCl), antineoplastics (e.g., capecitabine), antiparkinson agents (e.g., carbidopa, levodopa), antihypertensives (e.g., diltiazem HCl, irbesartan), analgesics (e.g., dextromethorphan, naproxen), anticonvulsants (e.g., gabapentin, lacosamide), antivirals (e.g., valacyclovir HCl) and contrast media (e.g., iopamidol, iohexol). Founded in 1990 and headquartered in Hyderabad, India, Divi's operates three manufacturing units with over 16,500 cubic meters of annual capacity, three R&D centers staffed by more than 700 scientists, and quality teams exceeding 2,000 analysts; it exports to over 100 countries across North America, Europe, Asia and other regions. In recent developments, Divi's entered a long-term manufacturing and supply agreement in May 2025 with an international pharmaceutical company for advanced intermediates, prompting plans to invest INR 650-750 crore in capacity expansion funded by customer advances, with operations targeted by January 2027; the deal anticipates meaningful long-term revenue contributions without external financing or structural changes. The company maintains a subsidiary, Divi's Nutraceuticals, and reported consolidated net profit growth to INR 662 crore in the March 2025 quarter alongside revenue of INR 2,585 crore.